NCT03768089View on ClinicalTrials.gov

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

May 3, 2019

Study Completion Date

May 3, 2019

Conditions
Cystic Fibrosis
Interventions
DRUG

Placebo (matched to VX-121 suspension)

Placebo matched to VX-121 suspension for oral administration.

DRUG

VX-121 (Suspension)

Suspension for oral administration.

DRUG

TEZ/IVA

Fixed-dose combination tablet for oral administration.

DRUG

IVA

Tablet for oral administration.

DRUG

Placebo (matched to TEZ/IVA)

Placebo matched to TEZ/IVA for oral administration.

DRUG

Placebo (matched to IVA)

Placebo matched to IVA for oral administration.

DRUG

VX-121 (Tablet)

Tablet for oral administration.

DRUG

Placebo (matched to VX-121 tablet)

Placebo matched to VX-121 tablet for oral administration.

Trial Locations (7)

Unknown

Academic Medical Center, Amsterdam

PRA Health Sciences Onderzoekscentrum UMCG, Groningen

UMC St. Radboud, Nijmegen

Erasmus Medical Center, Rotterdam

HagaZiekenhuis van den Haag, The Hague

Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham

The Medicines Evaluation Unit, Manchester

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT03768089 - Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis | Biotech Hunter | Biotech Hunter